Current Gemcitabine News and Events | Page 6

Current Gemcitabine News and Events, Gemcitabine News Articles.
Sort By: Most Relevant | Most Viewed
Page 6 of 6 | 208 Results
New generation of treatments shows promise for cancer patients
Armed with information about the function and capabilities of currently approved cancer therapies, researchers are beginning to develop more potent and successful treatments, according to research presented today at the 94th Annual Meeting of the American Association for Cancer Research (AACR). (2003-07-12)

U of MN Cancer Center researchers testing new drug combination to treat lung cancer
University of Minnesota Cancer Center researchers are studying a new drug combination to treat patients with non-small cell lung cancer. Led by Arkadiusz Dudek, M.D., Ph.D., the researchers are evaluating whether the drug Thalidomide will help enhance the cancer-killing ability of two chemotherapy drugs. (2003-03-17)

In elderly patients, combination chemotherapy no more effective than individual drugs
For elderly patients with advanced non-small-cell lung cancer (NSCLC), combination chemotherapy with the drugs vinorelbine and gemcitabine appears to be no more effective than either drug alone, but is more toxic, according to a study in the March 5 issue of the Journal of the National Cancer Institute. (2003-03-04)

Newer lung cancer treatments extend survival longer than traditional regimens
Patients with advanced non-small cell lung cancer who are treated with regimens containing paclitaxel and carboplatin survive longer than patients treated with older cisplatin-based regimens or supportive care, a new study finds. (2002-06-27)

Gemcitabine demonstrates promise as a low toxic chemotherapeutic agent for bladder cancer
Patients with bladder cancer could benefit from treatment with gemcitabine (Gemzar®), a chemotherapeutic agent that has been used successfully to treat pancreatic cancer and non-small cell lung cancer, according to phase I trial results reported at the 38th Annual Meeting of the American Society for Clinical Oncology (ASCO) by Merrill J. Egorin, M.D., professor of medicine at University of Pittsburgh Cancer Institute. (2002-05-19)

Chemotherapy trial proves the worth of including elderly patients in clinical trials
Doctors should be encouraged to include many more elderly people in clinical trials than they do at present, Dr Olavo Feher told the 3rd European Breast Cancer Conference in Barcelona today (Wednesday 20 March). Dr Feher, attending physician at the Hospital do Cancer in Sao Paulo, Brazil, said that the elderly were under-represented in clinical trials for cancer treatments, yet his research showed that useful results could be obtained if they were included in trials. (2002-03-20)

Marimastat produces comparable survival rates to chemotherapy in some advanced pancreatic cancer patients
An international team of researchers from the United States and Britain report that marimastat offers a similar survival benefit to chemotherapy in patients with non-metastatic pancreatic cancer, but with fewer side effects. A randomized clinical trial compared the effects of three different doses of marimastat, a matrix metalloproteinase inhibitor, with gemcitabine in 414 patients with advanced pancreatic cancer. (2001-07-30)

Fox Chase Cancer Center physician leads new international treatment study for ovarian cancer
An international clinical study to evaluate new treatments for women with ovarian cancer is now open in the U.S. This randomized study will compare the overall effectiveness of the standard treatment (a combination of paclitaxel and carboplatin) for ovarian cancer with recently developed chemotherapy combinations incorporating newer drugs. (2001-03-04)

Page 6 of 6 | 208 Results
   First   Previous   Next      Last is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to